Skip to main content

Table 3 The comparison between Patients with CRRT and non-CRRT who were in AKI stage 3

From: Continuous renal replacement therapy in patients with HIV/AIDS

 

AKI stage 3 (N = 63)

CRRT (N = 32)

non-CRRT (N = 31)

p

Male(%)

57 (90.5)

31 (96.9)

26 (83.9)

0.104

Age(years)

43 (37–50)

42 (37–56)

44 (36–48)

0.527

Blood routine and biochemical items

 Lymphocyte count(×109)

0.5 (0.24–1.00)

0.54 (0.34–1.05)

0.5 (0.2–0.8)

0.146

 Hemoglobin(g/L)

91 (70.8–108)

91 (71.8–109.5)

89 (70.7–104.5)

0.929

  Albumin(g/L)

27.4 (23.8–31.7)

30.3 (24.9–32.5)

26.8 (22.3–30.2)

0.027

  T-Bil (umol/L)

8.7 (5.8–15.9)

7.8 (5.1–14.5)

11.4 (6.3–16.0)

0.343

  Serum calcium(mmol/L)

1.92 (1.71–2.09)

2.0 (1.68–2.18)

1.88 (1.74–2.03)

0.221

 Lactate (mmol/L)

2.8 (1.45–6.05)

3.65 (1.55–7.15)

2.1 (1.35–5.0)

0.091

 Serum phosphate(mmol/L)

1.11 (0.81–1.65)

1.45 (0.81–1.88)

1.02 (0.81–1.36)

0.159

 LDH (U/L)

450 (309.6–786.6)

501 (281.6–1233)

450 (321.2–663.2)

0.336

Items related to HIV infection

 CD4 counts at ICU admission(cells/ml)

24 (8–86)

37 (13–116)

11 (5–36)

0.009

 HIV viral load (copies/mL)

1700 (90–249,112)

1650 (0–174,710)

37,444 (1142–335,614)

0.116

 HAART(%)

26 (41)

10 (31)

16 (51.6)

0.052

Complication

 PCP (%)

30 (47.6)

12 (37.5)

18 (58.1)

0.102

 Septic Shock(%)

41 (65.1)

19 (59.4)

22 (71)

0.245

Multiple Organs Support Therapy

 The use of vasoactive agents(%)

46 (73)

22 (66.8)

24 (77.4)

0.349

 Duration of Mechanical ventilation (h)

120 (7–240)

142 (5–256)

119 (14–212.5)

0.825

Severity of illness

 SOFA score at ICU admission (scores)

9 (7–13)

11 (7–14)

9 (6–11)

0.094

 APACHE-II score at ICU admission(scores)

23 (19–33)

28 (22–35)

19 (18–30)

0.015

Outcome

 Death during in ICU

34 (54)

18 (56)

14 (45.2)

0.521

 Renal recovery

17 (27.0)

7 (21.9)

10 (32.3)

0.353

 Length of ICU stay (days), median (IQR)

8 (5–14)

8 (5–15)

6 (5–14)

0.679

 Length of hospital (days), median (IQR)

16 (9–29)

15 (7–21)

17 (12–38)

0.029

  1. T-Bil Total bilirubin, HAART Highly Active Anti-Retroviral Therapy, PCP Pneumocystis carinii pneumonia, CRRT Continuous renal replacement therapy, ICU Intensive care unit, IQR Interquartile range, APACHE-II Acute physiology and chronic health evaluation, version II, SOFA Sequential organ failure assessment
  2. p Value < 0.05 was considered significant and is highlighted in bold